Back to search results

Empagliflozin for Arterial Stiffness in Aging

This study is looking at whether a medication called empagliflozin (10mg daily) can help reduce arterial stiffness (hardening of the arteries) in older adults. We are comparing empagliflozin to a placebo (a pill with no active medicine) over 12 weeks. You may be able to join if you are between 60 and 80 years old, and have evidence of arterial stiffness. The main goal is to see if empagliflozin can improve your carotid-femoral pulse wave velocity (cfPWV), which is a measure of arterial stiffness. The study plans to enroll 80 participants, but its current recruitment status is unclear.

Study design
This is a randomized, double-blinded, placebo-controlled study involving 80 participants (40 men and 40 women). Participants will receive either empagliflozin or a placebo daily for 12 weeks.
What's involved
You would take either empagliflozin or a placebo daily for 12 weeks. Your arterial stiffness (cfPWV) will be measured at the start, at week 4, week 8, and at the end of the 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks, with measurements taken at the end of this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06506422

Empagliflozin Reversal of Arterial StiffnEss in Aging

Recruiting
PHASE2Ages 60–80InterventionalTreatment
University of Missouri-Columbia
~80 participants
Updated 2026-02-06 on ClinicalTrials.gov
What's tested:Empagliflozin 10 MGPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Carotid Femoral Pulse Wave Velocity (cfPWV)
Measured over Baseline (day 0), Week 4, Week 8, Final (week 12)

Conditions

Aging
Arterial Stiffness

Explore related trials

AgingArterial Stiffness

NCT06506422

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Missouri

    Columbia, Missouristudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Camila Manrique, MD
[email protected]
(573) 882-2554
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to provide consent
60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses)
Stable anti-hypertensive medication regimen (if in use) for at least 90 days
Evidence of arterial stiffening (defined as carotid-femoral PWV \>/= 8 m/s) at the time of screening visit.

Exclusion

Diabetes
BMI\>/= 45kg/m2
Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
Estimated glomerular filtration rate GFR \< 29 mL/min
Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
Use of hormone replacement therapy
Body weight change ≥10% within the last 6 months
Uncontrolled hypertension during screening visit (\>180/110 mmHg)
Symptomatic hypotension and/or a SBP \<100 mmHg
History of ketoacidosis
High fall risk per assessment of study physician and/or safety officer at the time of screening (results must be abnormal for both fall risk assessments and orthostatic blood pressure measurements)
Anticipated need of prolonged fasting
History of recurrent UTIs or mycotic genital infections
Following a low-carbohydrate diet (\<20 grams/day)
Participation in regular exercise \> 3 days/week per week at a moderate or vigorous intensity
Known sensitivity to nitrate medications

What this trial measures

  • Carotid Femoral Pulse Wave Velocity (cfPWV)Baseline (day 0), Week 4, Week 8, Final (week 12)

    cfPWV is the gold standard non-invasive index of arterial stiffness. Transit time between carotid and femoral pressure waves is calculated using the foot-to-foot method. cfPWV is calculated as distance traveled by the pulse wave (i.e., femoral location-sternal notch minus sternal notch-carotid location) divided by pulse transit time. All the measurements will be done by the same blinded technician. The goal is to assess changes from baseline when compared to weeks 4,8, and 12 time points. Report